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Background: Men who undergo surgery for prostate cancer frequently experience significant side-effects including
urinary and sexual dysfunction. These difficulties can lead to anxiety, depression and reduced quality of life. Many
partners also experience psychological distress. An additional impact can be on the couple relationship, with
changes to intimacy, and unmet psychosexual supportive needs in relation to sexual recovery and rehabilitation.
The aim of this exploratory randomised controlled trial pilot study is to determine the feasibility and acceptability
of a novel family-relational-psychosexual intervention to support intimacy and reduce distress among couples
following prostate cancer surgery and to estimate the efficacy of this intervention.
Methods/Design: The intervention will comprise six sessions of psychosexual and relationship support delivered
by experienced couple-support practitioners. Specialist training in delivering the intervention will be provided to
practitioners and they will be guided by a detailed treatment manual based on systemic principles. Sixty-eight
couples will be randomised to receive either the intervention or standard care (comprising usual follow-up hospital
appointments). A pre-test, post-test design will be used to test the feasibility of the intervention (baseline, end of
intervention and six-month follow-up) and its acceptability to couples and healthcare professionals (qualitative
interviews). Both individual and relational outcome measures will assess sexual functioning, anxiety and depression,
couple relationship, use of health services and erectile dysfunction medication/technologies. An economic analysis
will estimate population costs of the intervention, compared to usual care, using simple modelling to evaluate the
affordability of the intervention.
Discussion: Given the increasing incidence and survival of post-operative men with prostate cancer, it is timely
and appropriate to determine the feasibility of a definitive trial through a pilot randomised controlled trial of a
family-relational-psychosexual intervention for couples. The study will provide evidence about the components
of a couple-based intervention, its acceptability to patients and healthcare professionals, and its influence on sexual and
relational functioning. Data from this study will be used to calculate sample sizes required for any definitive trial.
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Surgery is a major treatment modality for prostate can-
cer [1] and has been hypothesised to reduce mortality
more than other treatments for localised prostate cancer
[2]. However, the risks of surgery are known to include
erectile dysfunction [3] even when nerve-sparing ap-
proaches are used [4]. Long-lasting sexual and urinary
difficulties are the most common and troubling side-
effects following radical prostatectomy [5] alongside loss
of libido, ejaculatory dysfunction, orgasmic dysfunction
and penile shortening [6]. Even at 24 months post-
operatively, most men have not returned to their base-
line measure of sexual function prior to surgery [7].
These side-effects can be distressing for men and their
partners due to the impact on psychological well-being
and couple intimacy [8-11].
Many men affected by prostate cancer and erectile dys-
function experience symptoms of anxiety and depression
[12,13], with reduced quality of life directly associated with
urinary and sexual body-image changes that occur after
surgery [14]. Partners of these men also experience con-
siderable psychological distress [9,15-17], with anxiety and
depression often reported at higher levels for partners
than for patients [18,19]. The difficulties experienced after
surgery can also impact on the couple relationship itself;
for instance, erectile dysfunction is associated with re-
duced wellbeing [20,21] and lower levels of dyadic adjust-
ment in the first year after surgery [22].
Prostate cancer has been described as a ‘relationship
disease’ [23] and it has been established that couples af-
fected by prostate cancer often have significant unmet
psychosexual supportive care needs around sexual recov-
ery and rehabilitation [24,25]. With such evidence of the
impact of sexual dysfunction on relationships, there has
been increasing interest in the development of couple-
based psychosocial interventions that aim to improve well-
being and relationship quality. Couple-based interventions
have been effective in reducing psychological distress [26]
and facilitating healthy communication [27,28]. Sexual re-
habilitation therapy has been particularly helpful in in-
creasing use of erectile dysfunction medications [29] and
re-establishing a sexual relationship [30,31].
Evidence therefore exists to support the efficacy of
couple-based interventions for reducing psychological
distress, enhancing couple communication and improv-
ing relationship functioning among couples affected by
cancer [32]. Interventions for couples affected by pros-
tate cancer have targeted sexual functioning [31], rela-
tionship functioning [33], or combined both aspects
[19,28,29,34,35]. Reviewed systematically, the overall ef-
fectiveness of such interventions remains inconclusive
[36], although manualised face-to-face interventions that
address the connection between sexual difficulties and
relationship variables have shown improvements insexual functioning, including erectile function. Chisholm
et al. [36] conclude that the evidence remains weak due
to methodological limitations, such as small sample sizes
and ineffective outcome measures, while longer-term
gains in functioning have been limited.
Of particular note, interventions have not been suc-
cessful in improving both relationship and sexual func-
tioning [36]. Consequently, it would be beneficial to
devise an intervention framework that has a lasting im-
pact on sexual and emotional aspects of the couple
relationship. Studies suggest that understanding family-
of-origin relationships may be important in supporting
sexual functioning in marriage [37], and that to address
sexual issues it is critical to support the relationship
more generally [38]. Consequently, an approach which is
family-relational and psychosexual combines key ele-
ments of a potentially fruitful intervention.
The current study offers a family-relational-psychosexual
approach to supporting the couple, by combining family
systems principles with elements of sex therapy. Combin-
ing these approaches enables the intervention to address
broader relational issues that impact specific problems
around sex and intimacy. The intervention therefore has
the potential for long-term benefits to participants, as the
wider context of prostate cancer and couple dynamics are
a focus. It will develop a new way of supporting couples
that combines family systems principles with elements of
sex therapy to enhance intimacy and reduce distress. A
family systems approach is based on an understanding that
the family/relational context influences couple dynamics,
which consequently impact on relational and psychosexual
outcomes. The treatment model adopts a comprehensive
approach to couple support, addressing communication
and relationships within the family context, to address
broader relational issues in which specific problems around
sex and intimacy will be located.
Aims
The primary aim of the study is to determine whether
a family-relational-psychosexual intervention is feasible
and acceptable for couples affected by prostate cancer in
the context of one care-delivery setting. Subsidiary to
this, the study aims to understand what processes of
randomisation are plausible for a larger trial, determine
a sample-size calculation for a definitive trial, and esti-
mate the efficacy of the intervention to increase sexual
and relationship functioning.
Objectives
1. Design a family-relational-psychosexual treatment
for delivering a couple-based intervention.
2. Determine the acceptability and feasibility of the
intervention to patients, partners and healthcare
professionals in the context of one care-delivery setting.
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randomisation processes for a definitive trial.
4. Establish long-term cost implications to be
addressed in a definitive trial.
Methods
Design
This study has been designed to develop and assess the
feasibility of a couple-based intervention following pros-
tate cancer surgery. The design encompasses phases i/ii
of the Medical Research Council (MRC) complex inter-
vention framework [39,40]. It embeds a two-arm pilot
randomised controlled trial (RCT) followed by qualita-
tive interviews assessing acceptability and feasibility of
the intervention.
A pre-test, post-test design is being used to test the
feasibility of the intervention (baseline, end of intervention
and six-month follow-up). The study is underpinned by
Realistic Evaluation methodology, which acknowledges the
complexity of interventions and the contexts in which
they are delivered and assessed [41]. This methodology en-
sures that data is gathered from a range of relevant stake-
holders to identify facilitators and barriers to delivery and
uptake. The aim is also to produce findings that will be of
relevance in routine clinical practice.
Setting and participants
Patients with prostate cancer and their partners are be-
ing recruited from a single site in one National Health
Service (NHS) board: an outpatient surgical urology
clinic at the Western General Hospital, Edinburgh (NHS
Lothian), UK. The recruiting clinic sees patients from a
wide catchment area covering four Health Boards in
Scotland: the Borders; Dumfries and Galloway; Fife; the
Lothians. Recruitment will take place over one year.
Eligibility
Eligible patients are all men who: (1) are >11 weeks
post-operative for localised prostate cancer (to recruit
men who have recovered from the immediate effects of
surgery and who have consequently started to regain
some functioning); (2) have received surgery in the pre-
vious two years (since long-term adaptation will have
commenced in patients who have had surgery beyond
this timeframe); (3) have a partner (in an established
same-sex or different-sex relationship); (4) score ≤60
(the clinical threshold for potency [42]) on the sexual
function domain of the Expanded Prostate Cancer Index
Composite (EPIC).
Patients are excluded from the study if: (1) they have a
prognosis of ≤1 year (most men who have had recent
surgery will have a good prognosis, so it is unlikely that
many men will be excluded by this criteria); (2) they res-
ide in Dumfries and Galloway (to prevent excess burdentravelling to the intervention site); (3) they cannot pro-
vide informed consent; (4) they are unable to communi-
cate in English (this is a pilot trial, and if we move to a
full-scale trial in future we would seek to include inter-
preters/translators).
Sample size calculation
The trial aims to recruit 68 men and partners at routine
follow-up after surgery, with 30% over-recruitment to
enable adjustment for loss to follow-up [43]. A sample
size of 68 couples was calculated using G-Power [44]
based on having 90% power to detect a small-to-medium
effect size f of 0.20 on the primary outcome (using re-
peated measures analysis of variance (ANOVA) and
testing the within-between group interaction in this two-
group design with two points of measurement (end of
intervention and six-month follow-up) at an alpha level of
0.05). A small-to-medium effect on sexual function was
selected based on previous intervention effects seen for
couple interventions in the cancer literature [45].
Assuming a baseline mean of 33 and a standard devi-
ation of 24 on the sexual function subscale of the EPIC
[46], this study will have 90% power to detect a mean
difference of 9.6 units at the 0.05 level. This will allow
the study to estimate the efficacy of this intervention on
the mean difference in overall sexual function (as mea-
sured by EPIC) between the intervention and control
groups pre- and post-test. The standardised difference
observed will be used to calculate the sample size re-
quired for a definitive trial to test the efficacy of this
intervention. The anticipated effect size of f of 0.20 on
the primary outcome is a crude estimate, as it is based
on a pooled estimate of a heterogeneous selection of
couple interventions for several types of cancer [45].
Based on surgical data from the locale (2009 to 2011)
we estimate that there will be 500 patients who will be
between 12 weeks and two years from surgery during
the one-year recruitment period. The estimated recruit-
ment rate from a prior study with a similar population
and intervention design was 21% [33]. As some of the
patient population will be excluded from the study based
on the eligibility criteria above, we anticipate contacting
approximately 420 patients to recruit 88 couples (taking
account of 30% over-recruitment [43] to achieve a sam-
ple size of 68 couples completing the study).
Phase 1: designing the intervention
The intervention will be informed by the extant litera-
ture regarding the pragmatics and focus for the couple
work. It will consist of six sessions [34,35] conducted
every two to three weeks [28,47] by registered practi-
tioners at a local voluntary sector counselling organisa-
tion. The intervention will be delivered off-site in central
Edinburgh, away from the pressures of a busy outpatient
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discuss psychosexual concerns during healthcare consul-
tations [24].
The content of the intervention will comprise assistance
with emotional disclosure [33,48], psycho-education [19,29],
relational and sexual needs [29-31] and dyadic adjustment
and coping [49,50]. A treatment manual will be developed
to guide delivery of the intervention [51]. The manual will
comprise information about prostate cancer and its ef-
fects, principles of therapeutic change, guidance on using
the manual and a detailed session structure plan. This
manual-based family-relational-psychosexual support will
be based on systemic principles [52-55] combined with
techniques from sex therapy, that is, sensate focus [56].
Therefore, the manual aims to integrate components of
systemic theory with elements of sex therapy to support
intimacy and emotional aspects of the couple relationship.
Specialist training in delivery of the intervention will be
provided to practitioners holding accredited counselling or
psychotherapy qualifications. Training will include sessions
led by men affected by prostate cancer and a systemic
practitioner in cancer care. Fidelity to the manual will be
assessed as an ongoing process, recorded by practitioner
self-report using a checklist provided by the research team.
In line with routine counselling interventions, this
study adopts a waiting-list control design [57]. The con-
trol group will be offered the intervention if the analysis
indicates a significant benefit in quality of life for cou-
ples who receive the support.
The session structure for the intervention will cover
six main topic areas as follows:
Session 1 - Getting to know the couple: orientation
and engagement.
This first session will outline the support on offer.
Topics for discussion will include:
 the couple’s definition of current issues, concerns
and problems
 the cancer diagnosis and treatment(s)
 the partner’s role in the context of diagnosis and treatment
 mapping the support network and wider family system
Session 2 - The couple’s communication style and
relationship.
This session is primarily focused on understanding the
patient and their partner as a couple, to explore how
they convey love, support, understanding,
companionship and affection.
Session 3- Intergenerational patterns of illness, coping
and affection.
Focusing on intergenerational patterns, discussion will
centre on the role and meaning of illness in the couple
relationship in the context of: family resilience
 dyadic adjustment in ill-health
 the role of partners and family when someone is ill
 how people in the family express intimacy
Session 4 - Couple intimacy before and after cancer.
Intimacy before and after cancer will be explored. A
psycho-educational approach will be used to promote
closeness and express intimacy after treatment. The place of
medical treatments will be considered and techniques from
sex therapy will be applied if appropriate for the couple.
Session 5 - Further exploration of emerging areas.
This session will focus on areas that have emerged
in previous sessions where the practitioner and couple
wish to give more time to them. This may include
more work on increasing levels of intimacy, and
improving satisfaction with sexual activity, with
discussion of successes or challenges therein.
Session 6 - Summarising the couple’s accomplishments
and future planning.
The final session will summarise work to date, with
discussion of relapse prevention and how to take forward
progress that has been made, including the setting of
short- and long-term goals. This will include a specific
focus on maintaining intimacy and dyadic adjustment.
Phase 2: determining the parameters for a definitive trial
Patient recruitment
Eligible patients will be identified from the urology surgical
lists at the Western General Hospital, Edinburgh, UK. The
research nurse at the site will apply eligibility criteria before
patients are invited to complete the EPIC questionnaire.
Patients will be invited to complete the questionnaire via
two routes: either on-site at their post-operative follow-up
appointment at the outpatient surgical urology follow-up
clinic; or by postal invitation from the clinical team.
The recruiting site will complete logs to report recruit-
ment rates at baseline and any attrition following random-
isation. Additionally, attendance at the couple support
sessions will be logged to assess attrition rates at each
stage of the intervention. The recruitment rate for a larger
definitive trial will be calculated from the time taken for
68 couples to complete the study.
Route 1: outpatient surgical urology follow-up clinic
Participants will be recruited from the outpatient surgical
urology follow-up clinic. Clinic nurses will approach po-
tentially eligible patients and invite them to complete the
EPIC screening measure. Participants who are eligible
based on the EPIC score will be verbally notified, given
detailed information about the study, and provided with
baseline questionnaires and consent forms. A member of
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that patients may have.
When a nurse is not available, the study will be intro-
duced by the consultant/registrar during the consult-
ation; if interested in the study, the patient will then be
introduced to the researcher, who will provide detailed
information about the study and invite them to complete
EPIC.
Route 2: postal invitation from clinical team
This route will be adopted on days when the clinic is
very busy and there is consequently limited private op-
portunity for completing the EPIC screening tool. A let-
ter and detailed information sheet is sent to patients
who are potentially eligible. The letter invites them to
complete and return the EPIC questionnaire. The re-
search team will write to tell patients whether or not
they are eligible; if eligible, the remaining baseline ques-
tionnaires and consent forms are also issued at this time.
Randomisation, allocation concealment and blinding
Once consent is gained and baseline data (outcome
measures and demographics) are returned, patients
will be randomly assigned using block randomisation
with a 1:1 allocation ratio to receive the intervention
or standard care comprising their usual follow-up hos-
pital appointments. The allocation sequence is gener-
ated using computer software (GraphPad Software, La
Jolla, CA, USA) that randomly assigns subjects to the
control and intervention arms in blocks of 20. This
block randomisation process ensures equal numbers in
the intervention and control arms and removes selec-
tion bias [58].
A research administrator, who has no involvement in
the study, will assign participants to the control or inter-
vention arm according to the allocation sequence de-
scribed above. This individual will not be aware of the
allocation sequence until the moment of assignment.
In line with other designs of this type [59], blinding
will not be possible due to the nature of the interven-
tion and the acceptability component of the study. It
will be clear to study participants that they have been
allocated to the intervention or control group due to
the timing of data collection relative to receipt of the
intervention.
In order to establish if the intervention and control
group are clinically similar, the two groups will be com-
pared by physical health status. Consequently, the hospi-
tal’s audit officer will provide the research team with
anonymous data relating to clinical markers of disease
pathology. The markers are: (1) prostate-specific antigen
(PSA), a protein produced by the prostate that can be
measured in a man’s blood serum and used as a prog-
nostic indicator; when combined with (2) the Gleasonscore (GS), to differentiate the grade of tumour (from low-
to high-grade malignancy); along with (3) the tumour,
node and metastases (TNM) staging system to distinguish
localised from locally advanced and metastatic disease (the
degree of spread and involvement of lymph nodes) [60].
This clinical data will allow the team to determine
whether physical health status may be a confounding vari-
able in explaining any variance in the results of the trial.
In addition, ineligibility data will be recorded noting
number of patients and the reasons for their ineligibility.
Reasons for non-participation or withdrawal from the
study will be recorded to understand the acceptability or
otherwise of the support. However, in keeping with eth-
ical practice, potential participants will not be asked for
reasons for non-participation; this will only be noted if
proactively provided by patients or partners.
The recruitment and randomisation process is set out
in the CONSORT schema in Figure 1.
Data collection
As this is a feasibility study, it is not formally testing hy-
potheses. Nevertheless, we will examine outcome mea-
sures pre/post/follow-up (baseline, end of intervention
and six-month follow-up) to evaluate the indicative effect
of the intervention on both individual and couple/
relational issues. Outcome measures have been selected to
prevent over-burdening participants (by capping the
length and number of measures used). We have gener-
ously estimated that all measures may take 30 minutes to
complete, but feel that many participants will complete
them in 10 minutes. Validated measures, detailed below,
will be used alongside a specially designed pro forma for
collating additional information on health-service use and
demographic data.
In order to assess the feasibility and acceptability of
the intervention, practitioners will complete adherence
checklists, indicating for each couple which components
of the intervention were covered in the therapy.
Outcome measures
The primary outcome measure (see below) assesses sexual
functioning as part of a broader health-related quality-of-
life measure. The secondary measures reflect the evidence
that men and their partners require psychological (anxiety,
depression), relational and sexual components to an inter-
vention to meet the needs of this group.
Primary outcome measure
 Sexual functioning - EPIC measures general and
sex-specific items related to prostate cancer [46].
EPIC is a comprehensive instrument that evaluates
patient function and ‘bother’ after prostate cancer
treatment. Potency of ≤60 in the sexual function
domain is a clinical cut-off [42].
Figure 1 CONSORT schema.
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 Anxiety and depression - Hospital Anxiety and
Depression score (HADS) measures psychological
impact [61].
 Functional couple relationship - systemic core
outcome measure (SCORE 15) measures
relationship changes [62].
 Use of health services and erectile dysfunction
medication/technologies, collated via a self-report
questionnaire designed by the investigators.
Outcome measures will be assessed at baseline, at end
of intervention and six months later.
Statistical analysis
Although hypothesis testing should proceed cautiously in
a feasibility/acceptability study, we anticipate that couples
in the intervention group will show increased scores for
sexual functioning (measured using EPIC) and functional
couple relationship (SCORE 15 measure), and decreased
scores for anxiety and depression (HADS measure).
The study will therefore estimate the efficacy of this
intervention based on the mean difference in primary
(EPIC) and secondary outcome measures (SCORE 15,
HADS) between the intervention and control groups
pre- and post-test. Baseline demographic characteristics
will be reported as mean and standard deviation forcontinuous data and number (percentage) for categorical
data. ANOVA will be used to test the within-between
group interaction in this two-group design, with two
points of measurement (end of intervention and six-
month follow-up). Data will be managed and analysed
using SPSS version 19 (IBM Corp, Armonk, NY, USA).
The significance level applied to all analyses (and any ad-
justments for post hoc analyses) will be set at 0.05.
Analysis of the practitioner adherence checklist data
will proceed using frequency counts to identify those
areas addressed most frequently. This data will be inter-
preted with reference to the qualitative appraisal of feasi-
bility and acceptability.
Phase 3: qualitative assessment of acceptability and feasibility
In addition to the calculation of recruitment and reten-
tion rates, a qualitative approach will be used in the
post-trial evaluation to assess the acceptability of the
intervention. Interviews will be digitally recorded, tran-
scribed and managed using NVivo (version 10) software
(QSR International, Doncaster, Australia). The analysis
of transcripts will begin with thematic analysis, and
subsequently draw on systemic theory, to provide an in-
depth understanding of the acceptability of the interven-
tion. This is critical in gaining experiential accounts of
psychosexual and relational needs at follow-up to evi-
dence subjective outcomes.
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Individual face-to-face interviews will be conducted with
participants of the intervention group (N = 10 patients
and their partners) and control group (N = 10 patients and
their partners). Sampling will be purposive, with inter-
viewees stratified for degree of change, to determine quali-
tative appraisals of either usual care or the intervention
and its success or otherwise. Separate interviews will be
used to enable the exploration of private accounts of the
experience. Participants will be invited to opt in to an
interview when completing their post-intervention mea-
sures. The timing reflects the desire to gain feedback on
the intervention when recall is likely to be strongest.
Participants in the intervention group will be asked
about what was most and least helpful about the couple
support, the location and timing of this support, their rela-
tionship and use of services, and whether anything could
be changed or added to the intervention. Participants in
the control group will be asked about their routine care,
any support they received in relation to their quality of life,
sexual functioning, relationship and use of services.
Healthcare professional interviews
Post-intervention interviews will be conducted with key-
informant healthcare professionals (N = 10), including
those who have had experience of delivering the interven-
tion. Interviews will elicit views on the acceptability and
feasibility of the content and process of delivery of the
intervention; for example, eligibility criteria, method and
timing of recruitment, session structure, timing and dur-
ation of intervention. The suitability of the intervention
within the context of everyday care packages and current
prostate cancer provision in this locale will be assessed, to
consider questions such as whether the intervention works
better because it is off-site and away from clinical pres-
sures. Determining the acceptability and feasibility of this
single-site study will act as a starting point from which the
parameters of a definitive trial can be determined.
Establishing long-term cost implications
Economic analysis will focus on additional costs, com-
pared to usual care, and potential cost savings, using sim-
ple modelling to evaluate the affordability of the
intervention [63]. Data will be collected from the organ-
isation providing the intervention to provide estimates on
(i) duration of appointments, (ii) ‘did not attend’ rates,
and (iii) additional administrative activities. Data will also
be collected from participants on (i) contact with general
practitioner (GP), (ii) contact with hospital, (iii) use of
additional couple support to estimate cost savings to the
NHS. Modelling of this data will be applied to estimate
likely volumes and patterns of demand, and staff burden,
to estimate population-cost implications. Population costs
will be estimated using epidemiological data on prevalenceof men post-surgery for prostate cancer, alongside data on
attrition from the intervention.
Ethical considerations
The study has been approved by NHS West of Scotland
Research Ethics Committee (Reference: 12/WS/0255).
Management approval for recruiting at the Western
General Hospital site has been obtained from NHS
Lothian. A detailed information sheet will be provided to
participants with study information and contact details.
Informed consent will be obtained from all patients and
partners who agree to participate in the study. Add-
itional consent will be sought from those couples and
healthcare professionals who agree to take part in post-
intervention acceptability/feasibility interviews. If con-
sent is given by participants, GPs will be advised of their
patient’s involvement in the trial. Couples in the trial will
consent to having their baseline summary scores com-
municated to the practitioners delivering the interven-
tion; the use of outcome measures is routine practice
and helps practitioners tailor their approach to couples.
Data storage and confidentiality
Participants will be assigned a study number. All docu-
ments will be labelled with the study number alone, and
data stored on computers will only use this number. All
names referred to in the interviews will be changed fol-
lowing transcription and saved under the assigned study
number. Pre-anonymised transcripts will then be deleted.
Identifiable personal data will only be retained in the
following circumstances: consent forms will be stored in a
locked filing cabinet; couple names/addresses will be
stored in a locked filing cabinet and a password-protected
computer used in disseminating outcome measures and
final report/s.
Risks to participants
People diagnosed and treated for cancer constitute a
group that can be considered vulnerable. Consequently,
considerable care is required to ensure that adequate
safeguards are put in place.
Men recruited to the trial will not be in the immediate
aftermath of diagnosis. Recruitment to the study will only
occur when the man is at least 11 weeks past surgery.
Consequently, with current waiting lists, he is likely to be
approached about the study four to five months after diag-
nosis, and will have recovered considerably from surgery.
Further, only men who score ≤60 on the sexual function
domain of EPIC (the clinical threshold for potency) will be
invited to participate, so that the intervention is stratified
to target those men most in need of additional support.
Due to the nature of the disease, and our focus on re-
lational and psychosexual issues, it is likely that inter-
views touch on sensitive areas. The team has experience
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sitive issues and is aware of the potential emotional de-
mands on participants. Any participant who feels they
are unable to continue with an interview will be reas-
sured that it is permitted to withdraw from the research
at any time.
User involvement
The project has been designed to have user involvement
throughout. A group of men affected by prostate cancer
have helped design the methods and will continue to act
as consultants to the project. They have helped design
the intervention, train the practitioners, construct appro-
priate prompts for focus groups/interview schedules,
and will contribute to analysis and dissemination.
Discussion
Prostate cancer is the most common cancer in men. Sur-
gery is a major treatment modality for localised prostate
cancer. However, after surgery, men can suffer from sev-
eral side-effects like erectile dysfunction, anxiety and
decreased quality of life, which impact on wellbeing, in-
timacy and relationship quality. Men’s partners are also
influenced by these side-effects and can often experience
distress and reduced wellbeing. Yet previous research
has revealed that couples are not generally well sup-
ported to cope with these side-effects of surgery.
With an increase in the incidence and survival of post-
operative men with prostate cancer, there are significant
unmet psychosexual needs for couples affected by
prostate cancer. We aim to develop a family-relational-
psychosexual intervention for couples and then to test
the feasibility of this support in a pilot randomised con-
trol trial. We expect that sexual and relationship func-
tioning will be increased in couples who receive the
intervention, while distress will be reduced, compared to
those couples who receive standard care.
At the end of this study, we will have determined
whether the intervention is effective or not, and if it is ac-
ceptable to couples and healthcare professionals. An eco-
nomic analysis will estimate population costs. Therefore,
the study will provide evidence about the nature of a
couple-based intervention, its acceptability and influence
on sexual and emotional aspects of the relationship.
Trial status
Open - currently recruiting participants.
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